There was a statistically significant difference in shorter overall survival and higher risk of AML progression in patients with co-occurrence of SF3B1 and DNMT3A mutation than those with SF3B1mut but DNMT3A wild type (Martin et al., 2017). This evidence concerns the gene DNMT3A and acute myeloid leukemia.